Advaxis ADXS-HPV Project Selected as One of the Windhover and Campbell Alliance 2011 Top 10 Most Interesting Oncology Projects to Watch

Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been chosen by Windhover and Jonathon Fendelman of Campbell Alliance as one of the 2011 Top 10 Most Interesting Oncology Projects to Watch for the Advaxis ADXS-HPV immunotherapy program.

Tom Moore and Dr. John Rothman will present at Windhover’s Therapeutic Area Partnerships meeting taking place on November 30-Dec 2, 2011 at the Westin Copley, Boston.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive oncology opportunities the industry has to offer,” said David Cassak, vice president, content, Windhover Conferences, a division of Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability.”

About Windhover

Windhover Information Inc., an Elsevier company, has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more information please visit: http://www.windhover.com.

About Windhover’s Therapeutic Area Partnerships Meeting

Windhover Information's 6th Annual Therapeutic Area Partnerships is the industry's most targeted and efficient partnering meeting for life science companies seeking partnerships in the top therapeutic areas: Oncology, Cardiovascular/Metabolic, Neuroscience, Infectious, Inflammatory Diseases and more other hot therapeutic areas. For more information please visit: http://www.windhover.com/content/conferences/TA10-top10.html.

About ADXS-HPV

ADXS-HPV is an immunotherapy that is designed to treat human papilloma virus (HPV) associated diseases. Today, HPV is the most prevalent sexually transmitted disease in the US and the cause of cervical cancer, head and neck cancers of the oral pharynx, as well as a percentage of penile, vulvar, and anal cancers. ADXS-HPV is currently being evaluated in four Phase 2 clinical trials including two trials in cervical cancer, one in head and neck cancer, and one in CIN 2/3 (cervical intraepithelial neoplasia). Over 130 patients have been dosed to date in ADXS-HPV clinical trials.

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to Lm to the cancer, itself.

ADXS-HPV, Advaxis’ first construct is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer) with over 130 patients dosed to date. Over fifteen (15) distinct constructs are in various stages of development, either developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.